Articles tagged with: Daratumumab
Updated results of a key Phase 1/2 trial testing the potential new myeloma therapy daratumumab were released this morning. The new results confirm previous research indicating that single-agent daratumumab has notable activity as a multiple myeloma therapy.
Specifically, the results show that nearly one third of the trial participants – who had received a median of five prior therapies – responded to single-agent daratumumab. The median time to disease progression was 3.7 months, and the estimated one-year overall survival rate was 65 percent.
Daratumumab’s safety profile in the …
The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.
Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treatment and care.
During the meeting, there will be presentations about all types of cancer, including many presentations focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be presented, in one form or another, in connection …
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it …
This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer …
The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.
The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year. However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.
At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place. The presentations will summarize current research on a wide range of topics, including the biology of …